UNSPSC 51282309: Azithromycin anhydrous

This classification denotes a macrolide antibiotic with the molecular formula C38H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J2KLZ20U1M, chemically known as 11-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-2-ethyl-3,4,10-trihydroxy-13-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,6,8,10,12,14-heptamethyl-1-oxa-6-azacyclopentadecan-15-one but more generally known as azithromycin, which bears US NIH Compound Identifier 55185. Azithromycin most often comes in base and hydrate forms.

UNSPSC 51282309 Azithromycin anhydrous is a Commodity code that classifies individual pharmaceutical products for procurement by state and local health agencies. The recent contract activity under this code shows little direct alignment with azithromycin itself; instead, state and local procurement offices tag pharmaceutical supply contracts to this taxonomy when purchasing through cooperative purchasing vehicles and piggyback agreements with established pharmaceutical vendors. The work being solicited reflects state and local demand for consistent, bulk pharmaceutical supply through competitive bidding and cooperative purchasing frameworks — specifically, contracts awarded to vendors with established warehouse and distribution networks who can deliver multiple therapeutic agents on regular schedules with defined expiration windows and renewal terms.

Issuing bodies soliciting under this code include state departments of public health and county health authorities. The Illinois Department of Public Health executed a piggyback pharmaceutical warehouse contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026 for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with a total award of $2,999,999.11 over three years, while Seminole County, Florida issued an IFB for Naloxone and drug deactivation systems with quarterly delivery requirements. Geographic activity is present in Florida and Illinois; however, the code shows minimal recent open solicitation activity directly tied to azithromycin procurement, with available opportunities tagged to related pharmaceuticals rather than the specific active ingredient named in the code itself. The mismatch between the code's nominal scope and the actual products moving through recent awards suggests this Commodity code may see limited standalone pursuit activity in state and local markets.